Skip to content

AI in Drug Discovery & Development

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael

Hype, Reality, and What Comes Next

IndustryLife Sciences & Healthcare

AI has emerged as a powerful potential solution that could revolutionize how drugs are discovered, developed, and brought to patients. AlphaSense recently hosted an expert call with Dr. Paul Agapow, Former Director of Data Science at GSK, to discuss how AI is making inroads in this area.

Drawing from the call with Dr. Agapow, the latest data, and additional expert insights, this report covers how AI is performing against high expectations, what’s working, and what's not. This report also dissects the competitive arena, covering both today’s key players and the mergers, acquisitions, and collaborations that are defining the future.

About the Authors

  • Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.

  • Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
ReportAIFinancial ServicesTech, Media, & Telecom
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Report
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
ReportLife Sciences & Healthcare
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.